Literature DB >> 17174708

Generalised anxiety disorder.

Peter Tyrer1, David Baldwin.   

Abstract

Generalised anxiety disorder is a persistent and common disorder, in which the patient has unfocused worry and anxiety that is not connected to recent stressful events, although it can be aggravated by certain situations. This disorder is twice as common in women than it is in men. Generalised anxiety disorder is characterised by feelings of threat, restlessness, irritability, sleep disturbance, and tension, and symptoms such as palpitations, dry mouth, and sweating. These symptoms are recognised as part of the anxiety syndrome rather than independent complaints. The symptoms overlap greatly with those of other common mental disorders and we could regard the disorder as part of a spectrum of mood and related disorders rather than an independent disorder. Generalised anxiety disorder has a relapsing course, and intervention rarely results in complete resolution of symptoms, but in the short term and medium term, effective treatments include psychological therapies, such as cognitive behavioural therapy; self-help approaches based on cognitive behavioural therapy principles; and pharmacological treatments, mainly selective serotonin reuptake inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174708     DOI: 10.1016/S0140-6736(06)69865-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  72 in total

1.  The relation between sleep and pain among a non-clinical sample of young adults.

Authors:  Serge Brand; Markus Gerber; Uwe Pühse; Edith Holsboer-Trachsler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-03-31       Impact factor: 5.270

Review 2.  Contextual conditioning in rats as an animal model for generalized anxiety disorder.

Authors:  Laura Luyten; Debora Vansteenwegen; Kris van Kuyck; Loes Gabriëls; Bart Nuttin
Journal:  Cogn Affect Behav Neurosci       Date:  2011-06       Impact factor: 3.282

3.  An automated predator avoidance task in zebrafish.

Authors:  Omar Ahmed; Diane Seguin; Robert Gerlai
Journal:  Behav Brain Res       Date:  2010-07-30       Impact factor: 3.332

4.  Improving the detection and management of anxiety disorders in primary care.

Authors:  Marta Joanna Buszewicz; Carolyn Chew-Graham
Journal:  Br J Gen Pract       Date:  2011-08       Impact factor: 5.386

5.  Protocol for a randomised controlled trial investigating the effectiveness of an online e health application for the prevention of Generalised Anxiety Disorder.

Authors:  Helen Christensen; Kathleen M Griffiths; Andrew J Mackinnon; Kanupriya Kalia; Philip J Batterham; Justin Kenardy; Claire Eagleson; Kylie Bennett
Journal:  BMC Psychiatry       Date:  2010-03-21       Impact factor: 3.630

6.  Duloxetine in the treatment of generalized anxiety disorder.

Authors:  Alan Wright; Chad Vandenberg
Journal:  Int J Gen Med       Date:  2009-12-29

7.  Protocol for a randomised controlled trial investigating the effectiveness of an online e-health application compared to attention placebo or sertraline in the treatment of generalised anxiety disorder.

Authors:  Helen Christensen; Adam J Guastella; Andrew J Mackinnon; Kathleen M Griffiths; Claire Eagleson; Philip J Batterham; Kanupriya Kalia; Justin Kenardy; Kylie Bennett; Ian B Hickie
Journal:  Trials       Date:  2010-04-30       Impact factor: 2.279

Review 8.  The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.

Authors:  Baptiste Pignon; Chloé Tezenas du Montcel; Louise Carton; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2017-11-07       Impact factor: 5.285

Review 9.  Emotional memory function, personality structure and psychopathology: a neural system approach to the identification of vulnerability markers.

Authors:  Brian W Haas; Turhan Canli
Journal:  Brain Res Rev       Date:  2008-02-20

10.  Duloxetine in the treatment of generalized anxiety disorder.

Authors:  Trevor R Norman; James S Olver
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.